WORCESTER, Massachusetts, January 6, 2010/PRNewswire-FirstCall /-Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today two presentations of data from its on-going phase II study of his novel Immunotherapeutic AE37 vaccine in patients with breast cancer. The presentations entitled combination therapy: the a HER2/neu derived peptide vaccine sequentially manage security and immunological data from a phase II study or with Trastuzumab and increased prevalence of HLA dr3 in patients with breast cancer: implications for the adjuvant HER2/neu peptide vaccine studies, will be made at the 33rd Annual San Antonio Breast Cancer Symposium (www.sabcs.org) in San Antonio, Texas from December 8-12, 2010.
The presentation on combination therapy reports that patients have the AE37 Trastuzumab (Herceptin ®), a monoclonal antibody targeting the same protein, specific immune stimulation of T cells increases if AE37 simultaneous management of Trastuzumab instead of following Trastuzumab treatment is given. These results confirm the previous published suggesting that the combination of Trastuzumab with active immunotherapy for cancer patients can work synergistically reports.
The second presentation reported an immunological reaction AE37 have HER2 peptide vaccine patients, genetic predisposition to less efficiently from recognize the HER2 protein peptides are the robustness of the response in which is similar with this predisposition. This is a promising confirmation that AE37 as a self-potentiating peptide vaccine designed, has in fact improved activity, which can be clinically relevant.
The 2010 Antonio Breast Cancer introduces for cancer research and Baylor College of medicine CTRC-AACR San Symposium, an international scientific symposium for interaction and exchange between scientists and clinicians in breast cancer, cancer therapy and Research Center at the UT Health Science Center San Antonio, the American Association. The driving force behind this collaboration is ahead of the joint mission of the organizations, progress against breast cancer. By combining their respective strengths that includes San Antonio Breast Cancer Symposium the entire spectrum of breast cancer research and facilitates quick transition of new knowledge into improved care for patients with breast cancer.
About Generex Biotechnology Corporation
Generex engages in research, development and marketing of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs in the human body through the mouth (with no deposit in the lungs). The company's proprietary liquid formulations allow drugs are usually managed by injection into the body through the lining of the inner mouth using the company's proprietary rapid manure ™ device included. The company's buccal insulin spray product, Generex oral Lyn ™ approved for the treatment of patients with type 1 and type 2 diabetes in India Lebanon Algeria, Ecuador is in clinical trials of phase III at multiple sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. Express Antigen core platform technologies include Immunotherapeutic vaccines for the treatment of malignant, infectious, allergic and autoimmune diseases. For more information, visit the Generex website at www.generex.com or Antigen Express Web site at www.antigenexpress.com.
Safe Harbor statement
"Forward-looking statements" within the meaning of the private Securities Litigation Reform Act of 1995 contain this release and the oral explanations that from time to time can representatives to the same subject-matter of Generex. "" These instructions can be, identified by words such as "believes," ","Estimates,""Forecasts"," projects "" expected"will," "plans", "intends", or words of similar meaning, and by the fact that you not strictly to historical or current facts relate. Forward-looking statements are common when discussing potential product applications, potential partnerships, product development, clinical trials, regulatory submissions and approvals, and similar operation arrives. Many factors can cause that actual results from forward-looking, inaccurate assumptions and a variety of risks and uncertainties, of which some are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports saved by Generex with the Securities and Exchange Commission that should be considered together with forward-looking statements. A guarantee of future results or events is not forward-looking statements and you should avoid placing excessive reliance on such statements. Generex assumes no obligation to update statements, whether as a result of new information, future events public forward-looking or otherwise. Generex cannot be sure when or if it start agencies carry out additional clinical studies or any particular phase of clinical trials allowed will be. For this reason statements regarding the expected timing of clinical trials or ultimate regulatory approval can be considered the actual predictions if Generex receive approval for each "phase" of clinical trials or when it is received by a specific regulatory agency ultimate official authorisation. Generex claims the protection of the safe harbor for forward-looking statements is contained in the private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
Back to topRELATED LINKS
http://www.generex.com
No comments:
Post a Comment